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This study develops and evaluates a pharmaceutical consultation program (PCP) to improve treatment 
for Type 2 diabetes patients (T2DP) and reduce risk factors for diabetic complications with possible 
application in other chronic diseases. We recruited T2DP receiving conventional medical treatment 
but with fasting glycemia >140mg/dl and/or glycated hemoglobin >7%. The PCP includes strategies 
obtained from Dader’s method, the PWDT (Pharmacist´s Workup of Drug Therapy method) model 
of pharmaceutical care, the SOAP (Subjective data, Objective data, Assessment, and Plan of care) 
method, and concepts based on a nursing care model. The PCP evaluated lifestyle, pharmacotherapy 
and monitoring it using laboratory tests, vital signs, and anthropometry. These procedures were repeated 
every 4 months for 1 year. Data obtained in each consultation were used to provide patient education 
focusing on healthy lifestyles and medications. Fifty patients completed the PCP. There were reductions in 
glycemia (P<0.0001), glycated hemoglobin (P=0.0022), cholesterolemia (P=0.0072), triacylglycerolemia 
(P=0.0204) and blood pressure (P<0.0001). Increased concordance with drug treatment and correction 
of drug-related problems contributed to improved treatment. We can therefore conclude that our PCP 
was suitable for improving health outcomes in T2DP by reducing risk factors for diabetic complications.
Uniterms: Pharmaceutical care. Type 2 diabetes/treatment. Type 2 diabetes/pharmaceutical care. 
Pharmaceutical consultation. Glycated hemoglobin. Diabetes education. Pharmacy.
Neste estudo, desenvolvemos e avaliamos um programa de consulta farmacêutica (PCF) visando melhorar 
o tratamento de pacientes diabéticos tipo 2 (PDT2) e reduzir os fatores de risco de complicações diabéticas 
com possibilidade de aplicação em outras doenças crônicas. Para alcançar este propósito, PDT2 recebendo 
tratamento médico convencional, apresentando glicemia de jejum > 140 mg/dl e/ou hemoglobina glicada 
>7% foram selecionados. O PCF inclui estratégias obtidas a partir do método de Dader, do modelo de 
cuidados farmacêuticos PWDT (Pharmacist´s Workup of Drug Therapy method), do método SOAP 
(Subjective data, Objective data, Assessment, and Plan of care) e conceitos baseados em um modelo de 
cuidados em enfermagem. O PCF avaliou o estilo de vida, farmacoterapia e seu monitoramento através 
de exames laboratoriais, sinais vitais e antropometria. Estes procedimentos foram repetidos a cada 4 
meses durante 1 ano. Os dados obtidos em cada consulta possibilitaram oferecer educação focada no 
estilo de vida e uso de medicamentos. Para os 50 pacientes que concluiram o PCF houve redução da 
glicemia (P < 0.0001), hemoglobina glicada (P = 0.0022), colesterolemia (P = 0.0072), triacilgliceridemia 
(P= 0.0204) e pressão arterial (P < 0.0001). O aumento da concordância e a correção dos problemas 
relacionados a medicamentos contribuíram para melhoria do tratamento. Assim, podemos concluir que o 
PCF foi adequado para melhorar a saúde de PDT2 ao reduzir fatores de risco de complicações diabéticas.
Unitermos: Atenção farmacêutica. Diabetes tipo 2/tratamento. Diabetes tipo 2/cuidados farmacêuticos. 
Consulta farmacêutica. Hemoglobina glicada. Educação em diabetes. Farmácia.
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INTRODUCTION
Type 2 diabetes (T2D) has reached epidemic propor-
tions in Brazil (Silva et al., 2004; Bahia et al., 2011). For 
this reason, we adopted T2D as a model of disease where 
the pharmacist could help improve standard medical care 
(Silva, Bazotte, 2011; Zubioli et al., 2011). In this context, 
the Dader method could provide adjustments for improv-
ing glycemic control (Fornos et al., 2006).
However, application of the Dader method is lim-
ited due to the fact that Brazil is a large country with 
people living in widely varying socioeconomic condi-
tions (Angonesi, Sevalho, 2010). It is also difficult to de-
velop a pharmaceutical consultation program (PCP) that 
provides quality care for all patients equally in Brazilian 
community pharmacies. Furthermore, it must be consid-
ered that although the fundamental goal of the commu-
nity pharmacy is to provide suitable pharmaceutical care 
to each patient, Brazilian pharmacists are increasingly 
inundated with administrative responsibilities, leaving 
them less time to devote to direct patient care (Castro, 
De Castro, Correr, 2007). Our challenge, therefore, is 
to establish a new pharmacy community in our country 
where the pharmacist acts as a provider of health services 
helping to prevent disease and promote health. For this 
purpose, we developed and evaluated a PCP to improve 
T2DP treatment and reduce the risk factors for diabetes 
complications with the possibility of applying it to other 
chronic diseases.
Our PCP includes concepts from: 1) the Dader 
method of pharmacotherapy follow-up (Armando et al., 
2005; Sabater-Hernández et al., 2010) which comprises 
a service offer followed by scheduling the first interview 
when the patient brings his medicine bag; 2) the SOAP 
plan (Subjective data, Objective data, Assessment, and 
Plan of care) which is characterized by clinical docu-
mentation for patient care (Weed, 1970). Described in 
detail by Santana, Petris, López-Chozas (2010), this 
procedure is very important as the documentation is a tool 
in treatment reformulation (Zierler-Brown et al., 2007); 
3) The PWDT (Pharmacist´s Workup of Drug Therapy 
method) model of pharmaceutical care (Hepler, Strand, 
1990; Hepler et al., 2002; Strand et al., 2004); and 4) The 
Nursing Care Consultation of São Paulo Federal Univer-
sity, São Paulo, Brazil (Leite de Barros, Michel, Lopes, 
2002) modified and adapted for pharmaceutical care. 
Our pharmaceutical consultation program also includes 
strategies used in a previous study (Silva, Bazotte, 2011), 
communication based on face-to-face meetings, develop-
ing the pharmacist-patient relationship, and reinforcing 
lifestyle changes.
Thus, the purpose of this study was to develop and 
evaluate a PCP model to improve medical treatment by 
promoting a reduction in the risk of chronic complications 
in Brazilian T2DP.
PATIENTS AND METHODS
This intervention study was conducted in the 
Pharmacy School of Maringá State University, Maringá, 
Paraná State, southern Brazil which serves a wide socio-
economic range of patients. Consultations occurred inside 
the pharmacy in a private room, exclusively dedicated to 
pharmaceutical care.
The study was conducted within the ethical stan-
dards established by the Declaration of Helsinki and 
approved by Maringá State University Ethics Committee 
(COPEP - CAAE 197/2006).
The impact of our pharmaceutical consultation 
model was evaluated by comparing each patient before 
(month 0) and during treatment (month 4, 8, and 12). In 
other words, each patient served as their own control.
Fifty of the 55 individuals starting the program 
(March/ 2010) completed the study (March/2011).
Inclusion and exclusion criteria
Eligibility criteria included: T2D receiving standard 
medical treatment with fasting glycemia ≥140 mg/dL 
and/or glycated hemoglobin >7.0%. Exclusion criteria 
were: pregnancy, other specific types of diabetes, and 
absence at first consultation. 
Recruitment phase
Customers who visited the pharmacy school to 
acquire antidiabetic drugs and who declared a condition 
of medical treatment for Type 2 diabetes, were invited to 
participate in the study
During the recruitment phase (June/2009 – Decem-
ber 2009) 147 customers were invited to participate in this 
prospective study: 32 patients refused and a further 10 did 
not meet inclusion criteria. Reasons for refusing to partici-
pate were: avoid conflict with physician (15 patients), no 
time to attend the PCP (7 patients), claimed to know the 
problem well enough to waive participation in the study (8 
patients), having professionals other than their physician 
involved in the treatment (20 patients).
After selection, three patients did not attend the first 
consultation and were excluded. Two patients left the PCP 
after starting: one alleging advanced cancer, the other 
marital conflicts. 
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First consultation
Study subjects were invited to bring their recent 
medical exams (clinical laboratory results, electrocardio-
gram, electroencephalogram, radiological exams etc.) to 
the first consultation.
Immediately after giving their written consent the 
first consultation started with a 40 step interview (sum-
marized at the end of this section). 
After interview the following anthropometric data 
and vital signs were measured: systolic blood pressure 
(SBP), diastolic blood pressure (DBP), heart rate, radial 
pulse, respiratory frequency, body temperature, body mass 
index (BMI), waist circumference (man), waist circumfer-
ence (woman), waist/hip (man) and waist/hip (woman). 
For these parameters the following were considered nor-
mal values: <130 mm Hg, <80 mm Hg, 60-100 beats/min, 
60-100 beats/min, 16-20 breaths/min, <37 °C, <25 kg/m², 
<94 cm, <80 cm, <0.90 and 0.85, respectively.
Clinical laboratory tests
After the first consultation which lasted about 40-
50 minutes, patients received instructions for the clinical 
laboratory tests. Venous blood was collected from over-
night fasted patients and evaluated for blood glycated 
hemoglobin A1c (HbA1c), glucose, triacylglycerol, 
total cholesterol, and low and high density lipoprotein 
cholesterol (LDL-C and HDL-C). These tests were all 
repeated every four months. Patients also received cop-
ies of their lab test results tests, vital signs and anthro-
pometric parameters with instructions to show them to 
their physician.
Target values for HbA1c, glycemia, triacylglycerol, 
total cholesterol, LDL-C, HDL-C (men) and HDL-C 
(women) were <7.0%, 70-130 mg/dL, <150 mg/dL, 
<200 mg/dL, <100 mg/dL, >40 mg/dL, and >50 mg/dL, 
respectively. These values were based on the Clinical Prac-
tice Recommendation position statement of the American 
Diabetes Association (2010) and World Health Organiza-
tion recommendations (2012). 
First evaluation
From the lab results and data obtained in the first 
consultation an initial evaluation of the health problems 
(controlled and not controlled) was made. If some aspect 
of the treatment was considered “not controlled”, an ap-
propriate pharmaceutical intervention was made. If the 
“not controlled” condition was related to drug related 
problems (DRPs), this condition was classified (indication, 
effectiveness, safety, and non-adherence) as a preliminary 
step in the pharmaceutical intervention (Cipolle, Strand, 
Morley, 2004). It was then possible to formulate a plan 
for each individual to achieve the goals for improving 
their T2D control. For this, patients received guidance 
about diet, physical activity, the correct use of drugs, and 
resolution of DRPs. They were also informed about the 
risks of suffering chronic complications as a consequence 
of inadequate disease control. During the consultation the 
pharmacist gave each patient a more holistic view of their 
treatment and reinforced the recommendations made by 
their physicians.
Second, third, and fourth evaluation
The second, third and fourth consultations were 
made 4, 8, and 12 months after the first consultation, where 
the pharmacist repeated the first consultation procedure 
(except for unchanged information from the first inter-
view). All anthropometric and vital sign measurements 
were repeated to uncover the existence of new situations or 
the need for new interventions. From these consultations 
which lasted about 20-30 minutes together with the results 
from the lab tests, it was possible to retune the plan for 
each participant whenever necessary. Reformulations in 
treatment, particularly changes in dose and/or drug, were 
implemented by the physician.
Overview of the study design
Patient recruitment → patient selection → invita-
tion to first pharmaceutical consultation → signing of 
written consent → first pharmaceutical consultation 
(interview and evaluation of anthropometric data and 
vital signs) → clinical laboratory tests → second phar-
maceutical consultation (interview and evaluation of 
anthropometric data and vital signs) → clinical labora-
tory tests → third pharmaceutical consultation (interview 
and evaluation of anthropometric data and vital signs) 
→ clinical laboratory tests → fourth pharmaceutical 
consultation (interview and evaluation of anthropometric 
data and vital signs) → clinical laboratory tests → final 
evaluation.
Statistical analysis
Statistical analysis was performed using GraphPad 
Prism version 6.0 software. Results were analyzed by 
ANOVA and are reported as means ± standard deviation 
(SD). A 95% level of confidence (P<0.05) was accepted 
for all comparisons.
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Interview Schedule
1. Identification
1.1 Name: ______________________
1.2 Date: ___ /___ /___      1.3 Gender: _________
1.4 Date of birth: __/__/_ 
1.5 Marital status: ________
1.6 Place of Birth: __________
1.7 Phone number: ___________________ 
1.8. Place of Work:  ______________________________
1.9. Address and phone number: ____________________
1.10. Doctor (s) – responsible - Address and phone num-
ber: ___________________________
1.11. Pharmacist responsible for the interview: ________
_______________________________
2. Education: Illiterate (  ) – High school (  ) – Graduate (  ) 
– Post graduate (   ).
3. Profession: Current or prior (retired patient). Does the 
profession pose any risk to the patient’s illness and/or 
drug therapy?
4. Family: Number and age of children. Does the patient 
live with their children or parents? Do you have someone 
with diabetes in your family? Who? 
5. Social Interactions:  Normal (  ) - Does not make friends 
easily (  ) – Prefers to be alone (  ) – Does not adapt easily 
to new situations or places (  ).
6. Housing Conditions: Urban area (   ) – Rural area (  ) 
Apartment (  ) – With basic sanitation (  ) Without basic 
sanitation (  ).
7. Ability to Make Decisions: Make decisions quickly (  ) – 
It is difficult to make decisions (  ) – Often seeks help from 
family and friends (  ) – Cannot make decisions (  ).
8. Spiritual Beliefs: Has spiritual beliefs (  ) – Has no 
spiritual beliefs (  ) – Seeks spiritual support in difficult 
times (  ). 
9. Financial support: Private medical treatment (  ) – Pri-
vate health insurance (  ) – Public health assistance (  ) 
- Receives financial help from family (  ).
10. Health care guidance: Physician (  ) – Pharmacist (  ) 
Nurse (  ) – Prefers that family members receive orienta-
tions (  ) – Receives little guidance (  ) – Prefers not to talk 
about it (  ).
11. Self care:  Needs help with self care (  ) – Totally de-
pendent (  ) – Totally independent (  ).
12. View of the treatment: Is optimistic about the treatment 
(  ) - Is not optimistic about the treatment (  ) – Discouraged 
(  ) – Does not accept the problem (  ) – Does not care (  ).
13. Hospitalization and surgery: a). Have you ever been 
admitted to hospital? b) When was your last hospital stay? 
c) Why were you hospitalized? d) What type of treatment? 
e) Did you undergo any surgery? f) What type of surgery? 
14. Risk factors: Overweight (  ) – Smoking (  ) – Alcohol-
ism (  ) - Illegal drugs (  ) – Other (  ): 
15. Lifestyle 
Shower: Every day (  ) – Every other day (   ) – Once a 
week (  ) - Once a month (  ).
Brushing teeth: Every day (  ) – Every other day (  ) – Once 
a week (  ) - Once a month (  ).
Recreational activities: Travel (  ) – TV (  ) – Reading (  ) – 
Other activities (   ). What?
Physical Activity (exercise): No (  ). Yes (  ). If yes which 
one(s)? How many times a week?
16. Sleep: At what time you usually sleep? At what time 
you wake up? How long do you sleep per night? Do 
you have insomnia? Is it difficult to fall asleep? Do you 
wake up several times during the night? Do you feel 
daytime sleepiness? Do you sleep during the day? Do you 
snore too much? Do you have any other problem with 
sleep? 
17. Food ingestion: Do you follow a special diet? What 
kind? How many meals daily? Do you have a high intake 
of: fruit (  ) – Raw vegetables (   ) – Cooked vegetables 
(  ) – Red meat (  ) – Chicken (  ) – Fish (  ) – Juices (  ) – 
Coffee (  ) – Tea (  ) – Milk (  ) – Sweeteners (  ) – Vitamin 
supplements (  ) – Mineral supplements (  ).
18. Diseases of the digestive system: Normal (  ) - Peptic 
ulcer (  ) – Gastritis (  ) - Gastro esophageal reflux disease 
(  ) – Ulcerative colitis (  ) – Nausea (  ) – Vomiting (  ) – 
Hemorrhoids (  ) - Other abnormalities (  ). Which one (s)? 
19. Fecal elimination: Normal (  ) – Pain or another dif-
ficulty during defecation (  ) - Fecal urgency (  ) – Fecal 
incontinence (  ) – Constipation (  ) – Diarrhea (  ). How 
often do you defecate per day? 
20. Fluid ingestion: How much fluid do you consume each 
day? ______________   Water (  ) – Soft drink (  ) – Beer 
(  ) – Other: 
21. Kidney diseases: Kidney stone (  ), Renal failure (  ) – 
Hemodialysis (  ) – Other kidney diseases (  ). Which one 
(s)? 
22. Urinary elimination: How often do you urinate each 
day?  _________  Normal (  ) – Pollakiuria (  ) – Nocturia 
(  ) – Urinary urgency (  ) – Urinary incontinence (  ) – De-
creased urine stream (  ) – Difficulty urinating (  ).
23. Cardiovascular diseases: Normal (  ) – Hypertension 
(  ) – Angina (  ) – Tachycardia (  ) - Bradycardia (  ) – Ar-
rhythmia (  ) – Congestive heart failure (  ) – Heart attack 
(  ) - Other abnormalities (  ). Which one (s)? 
24. Lung diseases: Absence (  ) – Dyspnea (  ) – Asthma (  ) – 
Pneumonia (  ) - Bronchitis (  ) – Chronic obstructive 
pulmonary disease (  ) - Other abnormalities (  ). Which 
one (s)? 
25. Hepatic diseases: Absence (  ) – Steatosis (  ) – Ste-
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atohepatitis (  ) - Hepatitis (  ) – Cirrhosis (  ) – Other 
abnormalities (  ) - Which one (s)? 
26. Hematological diseases: Absence (  ) – Anemia (  ) – Ab-
normal coagulation (  ) – Leukocytosis or leucopenia ( ) – 
Other abnormalities ( ) – Which one (s)? 
27. Neurological diseases: Absence (  ) – Hemorrhagic or 
ischemic stroke (  ) – Headache (   ) – Seizure disorder (  ) – 
Migraine (  ) – Memory loss (  ) – Dizziness (  ) – Drowsi-
ness (  ) – Syncope (  ) – Other abnormalities (  ) – Which 
one (s)?
28. Psychiatric diseases: Depression (  ) – Psychosis (   ) – 
Mania (  ) - Other abnormalities ( ) – Which one (s)? 
29. Other endocrinal diseases: Hypothyroidism (  ) – Hy-
perthyroidism (  ) – Other endocrinopaty ( ) – Which one 
(s)? 
30. Other diseases/symptoms: Pain (  ) – Fatigue (  ) – 
Weakness (  ) – Other disease(s) ( ). Which one (s)? 
31. Physical examination to identify main health problems. 
Head: Normal (  ) – Dandruff (  ) - Scalp lesions (  ) – Hair 
loss (  ) – Other abnormalities ( ). Which one (s)? 
Eyes: Normal (  ) – Cataract (  ) - Blurred vision (  ) – Ab-
normal secretions (  ) – Other abnormalities ( ). Which 
one (s)? 
Nose: Normal (  ) – Allergy (  ) – Nasal obstruction (  ) 
– Epistaxis (  ) – Rhinitis (  ) – Other abnormalities (  ). 
Which one (s)? 
Mouth: Normal (  ) – Caries (  ) – Gingivitis (  ) – Missing 
teeth (  ) – Denture (  ) - Other abnormalities ( ). Which 
one (s)? 
Ears: Normal (  ) – Decreased acuity (  ) – Tinnitus (  ) – In-
flammatory or infectious processes (   ) - Labyrinthitis ( ) – 
Other abnormalities ( ). Which one (s)? 
Neck: Normal (  ) – Thyroid nodules (  ) – Enlarged thyroid 
– Other abnormalities (  ). Which one(s)? 
Upper limb: Normal (  ) Paresis or plegia (  ) – Lesions (  ) – 
Pain (  ) – Paresthesia (  ) – Other injuries (  ). Which one 
(s)? 
Abdomen: Normal (  ) – Pain (  ) – Flatulence or bowel 
sounds (  ) – Other abnormalities (  ). Which (s)? 
Lower limb: Normal (  ) – Edema (  ) – Pain (  ) – Paresthe-
sia (  ) – Loss of sensitivity (  ) – Paresis (  ) – Plegia (  ) – 
Lesions (  ) – Other injuries (  ). Which one (s)? 
Feet: Normal (  ) – Loss of sensitivity (  ) – Pain (  ) – Pares-
thesia (  ) – Lesions (  ) – Ulcers (  ) – Corns and calluses (   ) – 
Deformities (  ) – Edema (  ) – Amputation (   ) – Other 
abnormalities (  ) Which one (s)?
Skin: Normal (  ) – Age spots (  ) – Skin lesions: dermatitis, 
vitiligo, psoriasis, acne, infections, eruption (  ) – Dry skin 
(  ) - Excess hair (  ) - Edema (  ) – Allergic reactions (  ) – 
Eczema (  ) – lesions (  ) – Rash (  ) – Pale skin (  ) – Other 
injuries (  ). Which one (s)? 
32. Pharmacological profile:
a) What drugs are you currently using to treat diabetes? 
If you don’t remember please bring them to the next con-
sultation. 
b) What drugs are you currently using to treat other dis-
eases? If you don’t remember please bring them to the 
next consultation. 
c) What unprescribed drugs are you currently using? If you 
don’t remember please bring them to the next consultation. 
d) Do you use herbal teas or other alternative medicines 
or practices? Which one (s). How? 
e) Have you presented allergic reactions to medications? 
What drugs? 
f) Who administers your medications?
Observations: a) for prescribed drugs include: brand name, 
generic name, pharmaceutical form, dose and treatment 
schedule and times, and verify whether the drug is on 
the national list of essential drugs (RENAME, 2008); b) 
treatment regimen noted as: 1 (after breakfast) + 1 (after 
lunch) + 1 (after dinner). If there was absence of drug 
administration “1” is replaced by “0”. Additionally, if the 
patient forgot the information about his medication, he 
was reminded to bring the drugs and/or the prescription 
to the next consultation. 
33. Medication guidance: Physician (  ) – Pharmacist (  ) – 
Nurse (  ) – Prefers that family members receive guidance 
(  ) – Receives little guidance (  ). 
34. Drug side effects: Did you present symptoms indi-
cating drug adverse reactions. If yes: before starting the 
treatment (  ). After starting the treatment (  ). What did you 
feel? When? Which drug (s)? Which dose (s)? 
35. Drug interactions: Did you present symptoms indicat-
ing drug interactions. If yes: before starting the treatment 
(  ) – After starting the treatment (   ). What did you feel? 
When? Which drug (s)? Which dose (s)? 
36. Drug compliance: Yes (  ). No (  ). If no: Why? When? 
Which drug (s)? Which dose (s)? 
37. Drug related problem: Yes (  ). No (  ). If yes: Which 
one (s)?
a) Classification: Indication (   ), Effectiveness (    ), Safety 
(    ) and Non adherence (     ).
38. Pharmacist’s opinion on patient’s appearance: Good 
(G) or Bad (B): Clothing (  ) - Hair (  ) – Nails (  ) – Oral 
care (  ) – Body care (  ).  
39. Final question: is there anything else you would like 
us to know?
40. Pharmacist’s opinion about the patient’s health prob-
lem: controlled (C) or not controlled (NC). If NC: What is 
(are) not controlled? What is the appropriate pharmaceuti-
cal intervention? 
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RESULTS
The patients (25 men and 25 women) had a mean 
age of 58.6 ± 7.8 (mean ± SD) years (range 36-75 years). 
Additionally, 64% of the patients had ≥ 5 years of diagno-
sis with time of diagnosis: 11.2 ± 8.4 (mean ± SD) years, 
ranging from 2 to 38 years. Interestingly, 48% had private 
health insurance and 52% used the public health system.
The physician (68%) and the pharmacist (44%) 
were the most sought after professional for guidance on 
health and drug problems, respectively. In addition, 50% 
of the T2DP had not received guidance on drug use before 
starting the study. 
The main abnormalities detected from interviews, 
and anthropometric data and vital sign evaluation were 
hypertension (76%), overweight or obesity (48%), tachy-
cardia (48%), skin age spots (22%), lower limb edema 
and pain (22%), upper limb pain (20%), flatulence or 
bowel sounds (18%), lower limb lesions (18%), upper limb 
edema and lesions (16%), kidney stones (16%), migraine 
(14%), gastritis (14%), abdominal pain (12%), foot pain 
(12%), cataract (12%), upper limb paresthesia (10%), 
blurred vision (10%), thyroid complaints (10%), gastro 
esophageal reflux (8%), eye discharge (8%), constipation 
(6%), diarrhea (6%), sinusitis (6%), labyrinthitis (6%), 
foot deformities (4%), paresthesia in the feet (4%), foot 
edema (4%), renal failure (4%),  peptic ulcer (4%), hemor-
rhoids (4%), and tinnitus (4%).
Concerning hospitalization 52% patients were 
hospitalized in the last 7 years. However the majority of 
hospitalizations (44%) were not related with the diabetes.
Sleep was not satisfactory for 54% T2DP: insomnia 
(2%), sleep medication (6%), sleeping difficulty (18%), 
waking up several times in the night (16%), sleeping dur-
ing the day (8%), and sleepiness (4%).
Changes in lifestyle were detected. For example, 
regular physical activity increased from 30% (month 0) 
to 64% (month 12). From these results the percentage 
of patients engaged in the nutritional education process 
increased from 14% (month 0) to 76% (month 12). 
Oral antidiabetic drugs were used in mono (32%) or 
combined (68%) therapy. Metformine was present in all 
combined antidiabetic drug treatments. Metformine (iso-
lated or combined) was used by 44 patients (88%), glicla-
zide by 11 (22%), glimepiride by 8 (16%), glibenclamide 
by 7 (14%), clorpropamide by 1 (2%), vildagliptine by 3 
(6%), sitagliptine by 1 (2%), and rosiglitazone by 1 (2%).
Regimens for oral antidiabetic drugs were: a) once 
a day: metformine (n=1), gliclazide (n=9), glibenclamide 
(n=1), glimepiride (n=7), vildagliptine (n=1); b) twice a 
day metformine (n=25), gliclazide (n=2), glibenclamide 
(n=5), glimepiride  (n=1), clorpropamide (n=1), vildaglip-
tine (n=2), sitagliptine (n=1), rosiglitazone (n=1); c) three 
times a day: metformine (n=18), glibenclamide (n=1).
Insulin was used by 18% of T2DP. The regimen was: 
a) NPH: once a day (n=3), twice a day (n=1); b) Regular: 
twice a day (n=1); b) NPH + Regular: once a day (n=1); c) 
glargine: once a day (n=2), twice a day (n=1). We also ob-
served that insulin was used on its own (n=1) or combined 
with metformine (n=4), clorpropamide (n=1), gliclazide 
(n=1), glimepiride (n=1), or vildagliptine (n=1).
Antihypertensive, lipid lowering, antiplatelet, and 
over the counter drugs were used by 31 (62%), 11 (22%), 
8 (16%), and 18 (36%) patients, respectively.
Prescribed and non-prescribed pharmaceutical drugs 
included the following: acetylsalicylic acid, alendronate, 
aminophylline, amoxillin, alprazolam, amitriptyline, 
amlodipine, atenolol, bezafibrate, bromazepam, budeso-
dine, butylscopolamine, carbamazepine, cyclobenzaprine, 
clonazepam, cloxazolan, captopril, celoxib, cilostazol, clo-
rtalidone, clopidogrel, condroitin, diclofenac, diltiazem, 
dimenidrate, domperidone, enalapril, eplerenone, spirono-
lactone, folic acid, formoterol, hydrochlorothiazide, indap-
amide, fenitoin, ferrous sulfate, furosemide, ginkgo biloba, 
lorazepam, levofloxacin, losartan, meloxicam, methyl-
dopa, naproxen, nitrofurantoin, nitroglycerin, nifedipine, 
omeprazole, paroxetine, pentoxifylline, predinisolone, 
propranolol, ramipril, rosuvastatin, sibutramine, sidenafil, 
simvastatin, valsartan, thyroxine, and ziprasidone.
Table I  shows improvements for glycemia 
(P<0.0001), HbA1c (P=0.0022), total cholesterol 
(P=0.0072), HDL (p=0.0042), triacylglycerol (P=0.0204), 
SBP, and DBP. In the specific case of SBP (P<0.0001) and 
DBP (P<0.0001) the reduction occurred 4 months after 
starting the PCP.  However, BMI and waist circumference 
remained unchanged.
DISCUSSION
The role of pharmaceutical care in improving pa-
tient health outcomes is well established (Brooks, Rihani, 
Derus, 2007; Lyra, Marcellini, Pelá, 2008; Al Mazroui et 
al., 2009).  However, there is a need for a pharmaceuti-
cal care model suitable for applying in Brazil where the 
health care system is very different to countries where the 
main pharmaceutical care methods have been developed 
(Obreli-Neto, Cuman, 2010; Correr et al., 2009a,b; Correr 
et al., 2011).
For this reason our PCP incorporates concepts from 
several well established patient care methods (Armando 
et al., 2005; Weed, 1970; Leite de Barros, Michel, Lopes, 
2002; Hepler, Strand, 1990). Selecting the best aspects of 
Pharmaceutical consultation as a tool to improve health outcomes for patients with type 2 diabetes 91
TABLE I - Profiles of the patients before (month 0) and 4, 8, and 12 months after starting the pharmaceutical care program (PCP)
Parameters month 0 month 4 month 8 month 12 P values # P values § P values *
GLY 183.4±7.3 164.8±7.4 158.7±7.2 143.9±5.5 0.0769 0.0182 <0.0001
HbA1c 9.6±0.3 8.8±0.33 8.5±0.3 8.15±0.3 0.1082 0.0288 0.0022
TC 220.0±5.6 213.1±6.9 208.9±5.9 196.3±6.1 0.4428 0.1837 0.0072
HDL-C 35.6±1.4 38.57±1.7 39.35±1.3 41.57±1.4 0.1829 0.0539 0.0042
LDL-C 130.4±4.7 129.5±6.4 128.2±4.4 118.1±4.9 0.9185 0.7395 0.0743
TG 209.1±15.5 213.3±18.8 192.6±22.4 161.0±12.7 0.8622 0.5475 0.0204
SBP 157.0±3.2 133.4±3.4 130.7±2.2 126.6±1.3 <0.0001 <0.0001 <0.0001
DBP 107.6±2.7 93.7±2.7 89.9±2.0 85.73±1.2 0.0004 <0.0001 <0.0001
HR 115.0±3.2 108.3±6.5 104.8±7.1 99.0±6.2 0.3692 0.2110 0.0379
RP 117.4±3.5 109.1±8.0 105.7±8.0 99.4±6.8 0.3664 0.2040 0.0361
RF 21.6±0.63 19.3±0.44 18.2±0.61 18.1±0.6 0.0047 0.0004 0.0002
BMI > 25 31.1±0.65 30.8±0.7 30.7±0.7 30.5±0.7 0.7827 0.7411 0.5611
BMI > 30 33.6±0.63 33.4±0.72 33.3±0.7 33.1±0.7 0.8315 0.7662 0.6108
W/H 0.99±0.008 0.99±0.008 0.98±0.008 0.98±0.008 0.8129 0.8683 0.3723
Data are means ± standard deviation (50 patients). P values were obtained after comparing month 0 with month 4 (#), month 0 with 
month 8 (§), and month 0 with month 12 (*). Key: GLY (glycemia – mg/dL), HbA1c (glycated hemoglobin A1c - %), TC (total 
cholesterol - mg/dL), HDL-C (high density lipoprotein cholesterol - mg/dL), LDL-C (low density lipoprotein cholesterol - mg/dL), 
TG (triacylglycerol - mg/dL), SBP (systolic blood pressure - mmHg), DBP (diastolic blood pressure - mmHg), HR (heart rate - beats/
min), RP (radial pulse - beats/min), RF (respiratory frequency - breaths/min), BMI (body mass index - kg/m²), W/H (waist/hip).
each method resulted in the PCP described in this paper. 
The contribution made by each strategy cannot be evalu-
ated, but results showed that providing diabetes educa-
tion and reinforcing lifestyle changes can help patients 
optimize metabolic control in a country where only 0.2% 
of T2DP simultaneously reach targets for glycemia, lipid-
emia, and blood pressure (Gomes et al., 2006). Additional 
details on the contribution by each method can be found 
in Zubioli (2011).
The main limitation of our PCP is the time needed 
(40-50 min) in the first consultation to obtain all the re-
quired information. But, the availability of this information 
for other professionals, particularly the physician, could 
be important by supplying relevant clinical data which 
is difficult to acquire in a regular medical consultation. 
In accordance with this statement, of the 50 T2DP who 
concluded the study, more than 350 abnormalities and/or 
diseases were able to be detected, about 7 per patient.
The success of our PCP in promoting a reduction 
in chronic complication risks in Brazilian T2DP is sum-
marized the Table I. Similar results were obtained when 
male (n= 25) and female (n= 25) or optimist (n=29) and 
non-optimist (n=21) patients were compared (results not 
shown).
Improvements in fasting glycemia, HbA1c, triacyl-
glycerol, total cholesterol, HDL-C, SBP and DBP show 
the importance of monitoring not only glycemia but also 
blood pressure and lipid profile to obtain a reduction in 
cardiovascular risks, the main cause of death in T2D 
(Azambuja et al., 2008; Kothari et al., 2002). 
The DCCT (1993) and UKPDS (1998) studies 
demonstrated a clear reduction in the chronic complica-
tions associated with a 1.0% reduction in HbA1c levels 
in Type 1 and Type 2 diabetes patients, respectively. The 
reduction in HbA1c obtained in this study, i.e., 1.45% is 
very relevant and suggests that our PCP together with the 
medical treatment represents a suitable approach for T2DP.
Changes in lifestyle certainly contributed to these 
improvements. At the start of the PCP 30% of the patients 
were engaged in regular physical activity, but due to con-
stant reinforcement of lifestyle changes by the pharmacist, 
this percentage increased to 64%. Improvement in regular 
physical activity is a benefit, even without weight loss, 
because it will prevent weight gain, abdominal obesity, 
and insulin resistance favoring better glycemic control 
and decreasing cardiovascular risk (Clifford et al., 2005; 
Castro et al., 2006; Coleman et al., 2007). Additionally, 
14% of the patients were engaged in the nutritional educa-
tion process when the PCP started, but due to continuous 
encouragement from the pharmacist towards nutritional 
changes, this percentage increased to 76%.
In contrast, BMI and waist circumference remained 
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unchanged after one year of follow up (Table I). For this 
reason future studies must include new strategies based 
on reducing body weight by 5 to 10%, as this represents a 
significant improvement in metabolic control, blood pres-
sure levels, and a reduction in diabetes related mortality 
(Ahrens, Hower, Best, 2003).
Evaluation of our PCP needs to take in to account 
several methodological limitations: potential selection 
bias, the possibility of behavior changes by the patients 
simply because they are being studied (Lindenmeyer et 
al., 2006), the limited number of patients etc. However, 
despite these limitations our PCP is suitable for application 
and may be used in the private community pharmacy chain 
and could also be adapted for the public health system and 
for other chronic diseases.
CONCLUSION
The PCP developed in this study was suitable for 
improving health outcomes in T2DP by reducing the risk 
factors for diabetes complications.
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